Ibrahim Balghith Awadh

Dr. Ibrahim Balghith Awadh


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 January 2023 in Life
Verified
Journal Article
Open access
PDF file
Patel MiteshPatel Mitesh
Patel Mitesh
Mohd AdnanMohd Adnan
Mohd Adnan
AAAbdu Aldarhami
Abdu Aldarhami
Abdulrahman S BazaidAbdulrahman S Bazaid
Abdulrahman S Bazaid
NSNizar Saeedi
Nizar Saeedi
KAKhalid Alshaghdali
Khalid Alshaghdali
In the wake of the emergence and worldwide respread of a viral infection called Monkeypox (Mpox), there is a serious threat to the health and safety of the global population. This viral infection was endemic to the western and central parts of Africa, but has recently spread out of this endemic area to various countries, including the United Kingdom (UK), Portugal, Spain, the United States of America (USA), Canada, Sweden, Belgium, Italy, Australia, Germany, France, the Netherlands, Israel, and Mexico. This is a timely review focusing on recent findings and developments in the epidemiology, clinical features, therapeutic targets, diagnosis, prevention mechanisms, research challenges and possible treatment for Mpox. To date (29 November 2022), there have been around 81,225 reported cases of Mpox. In most cases, this illness is mild; however, there is a fatality rate ranging from 1 to 10%, which might be increased due to associated complications and/or secondary infections. There is a real challenge in the diagnosis of Mpox, since its symptoms are very similar to those of other infections, including smallpox and chickenpox. Generally, to prevent/limit the risk and transmission of Mpox, the detection and isolation of infected individuals, as well as hand hygiene and cleanliness, are essential and effective approaches to control/combat this viral infection. Nevertheless, updated information about Mpox from different angles is lacking. Thus, this review provides updated and comprehensive information about the Mpox illness, which should highlight the global burden, pathogenicity, symptoms, diagnosis, prevention measures and possible treatment of this emerging disease.

10 October 2025 in Medicine
Verified
Journal Article
Open access
AAAbdu Aldarhami
Abdu Aldarhami
MEMahmoud Elrggal
Mahmoud Elrggal
RARahma Ali
Rahma Ali
KAKhairiah K Almushri
Khairiah K Almushri
MAMusedah A. Alamri
Musedah A. Alamri
Abdulrahman S BazaidAbdulrahman S Bazaid
Abdulrahman S Bazaid
Antimicrobial resistance (AMR) is a growing global health concern, especially in critically ill patients with multiple comorbidities. This study aimed to investigate bacterial resistance patterns in these patients and to explore the correlation between resistance prevalence and patient characteristics. A retrospective study was conducted at Al-Qunfudah General Hospital, Saudi Arabia, analyzing microbiological data from critically ill patients diagnosed with bacterial infections and/or conditions such as sepsis, urinary tract infections, kidney diseases, and COVID-19 between 2018 and 2022. Bacterial identification, susceptibility profiles, and demographic information were included to assess potential correlations. A total of 423 patients were included, with males comprising 61%. Gram-negative organisms constituted the majority of bacterial isolates (79.9%), with Klebsiella pneumoniae, Pseudomonas aeruginosa , and Acinetobacter baumannii being the most prevalent and exhibiting high resistance rates. In contrast, Gram-positive bacteria showed lower resistance rates, with Streptococcus species and Staphylococcus aureus being the most common, displaying high resistance to penicillin and erythromycin. This study demonstrates concerning levels of multidrug-resistant bacteria in critically ill patients, posing serious therapeutic challenges. Gram-negative bacteria showed higher resistance rates than Gram-positive strains. The findings highlight important trends and underscore the need for ongoing surveillance and updated treatment strategies. Further multicenter prospective studies with inferential analysis are recommended to confirm associations and guide clinical decision-making.

31 July 2026 in Medicine
Verified
Journal Article
Open access
AAAbdu Aldarhami
Abdu Aldarhami
RARahma Ali
Rahma Ali
IAIbrahim Balghith Awadh
Ibrahim Balghith Awadh
RSRaja Sassi
Raja Sassi
HAHassan Alzahrani
Hassan Alzahrani
Abdulrahman S BazaidAbdulrahman S Bazaid
Abdulrahman S Bazaid
Rationale: Autoimmune hemolytic anemia is a rare but potentially life-threatening complication of Plasmodium vivax malaria. Most reported cases required corticosteroid therapy in addition to antimalarial treatment. Patient concerns: We report the case of a 28-year-old Ethiopian man who presented with fever, pallor, and fatigue. Diagnosis: Laboratory evaluation revealed severe anemia (hemoglobin 6 g/dL), thrombocytopenia (88,000/µL), hyperbilirubinemia, and a positive direct antiglobulin test. Peripheral smear confirmed P vivax infection with 2% parasitemia. Comprehensive immunohematological testing, including direct antiglobulin test, elution, adsorption, and extended antigen typing, confirmed immune-mediated hemolysis and excluded alloantibody-related incompatibility. Interventions: The patient received 3 compatible blood transfusions and was treated with intravenous artesunate followed by primaquine, without corticosteroids or platelet transfusion. Outcomes: By day 5, hemoglobin improved to 10.2 g/dL, platelets normalized, and malaria smears were negative. He was discharged in stable condition. Lessons: This report highlights an unusual presentation of P vivax malaria complicated by severe autoimmune hemolytic anemia and thrombocytopenia, which resolved with antimalarial therapy alone, without immunosuppressive therapy, including corticosteroids. This finding suggests that corticosteroids may not always be necessary in certain cases and underscores the importance of early recognition and comprehensive immunohematological evaluation in malaria-related cytopenias.